ASBP
Aspire Biopharma Holdings, Inc. (ASBP) Economic Moat Analysis (2026)
Overall Score
Scale Market Position
ASBP remains a micro-cap with a market cap of about $1.0M, limiting evidence of durable scale advantages.
Revenue per share is only $0.09 TTM, indicating an extremely small operating base.
Pricing Power Margins
Gross margin is only 18.3% TTM, while EBIT margin is deeply negative at -64.7%, showing weak pricing power and poor operating leverage.
Net profit margin is -113.1% TTM, reinforcing that the business is not converting sales into durable profits.
Customer Stickiness Retention
No fresh evidence indicates recurring revenue, contractual lock-in, or other retention advantages.
The extremely low asset turnover and working-capital inefficiency suggest a business without clear operating stickiness.
Intangible Assets Switching Costs
No material evidence of patents, brands, or proprietary assets supporting a moat.
Intangibles are 0% of total assets, which does not support meaningful intangible-driven defensibility.
Cost Advantage Operating Efficiency
Operating efficiency remains poor, with operating cash flow sales ratio at -73.6% and working capital turnover at 0.01x.
Inventory and payables days are extremely elevated, suggesting inefficient operations rather than a structural cost advantage.
Network Effects Ecosystem
No evidence of network effects, platform dynamics, or ecosystem lock-in in the available data.
The company’s tiny scale and lack of revenue momentum do not indicate a self-reinforcing moat.
Financial Strength Resilience
Liquidity is strong, with a current ratio of 8.0x and cash ratio of 7.2x, which supports near-term resilience.
The balance sheet shows no debt, but profitability and cash generation remain weak, limiting long-term moat durability.
Moat Durability Outlook
The current data still does not show a durable economic moat, as profitability, scale, and efficiency remain very weak.
Strong liquidity provides survival support, but it does not by itself create competitive advantage.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Aspire Biopharma Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

